All News
Digital Platforms and AI
2026 EULAR Press Release
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
Read Article
WIN Nutrition session at #EULAR2026 (1)
🫐Higher fruit intake → RR 0.88 & cereal intake → RR 0.87 for RA onset
🥩 Highest quartile of red & processed meat intake → nearly DOUBLE the risk of RA onset (OR 1.92, CI 1.11–3.35)
@rheumnow https://t.co/RhO08FXtLI
Nelly ZIADE 🍀 Nellziade ( View Tweet)
COMPARE Ph I trial CD19 CAR T-cell ACPA+ refractory RA
6 pts median 6.5 b/tsDMARDs
Single CAR T infusion after lymphodepletion
Safety
-CRS only grade 1–2 (no severe events)
-No ICANS
-Transient neutropenia
-No unexpected toxicities
Efficacy
DAS28-CRP ↓ ~41% median
50% achieved https://t.co/cdEfGKcJUp
Aurelie Najm AurelieRheumo ( View Tweet)
D2T RA shows a linked brain–psychology–immune signature
Cohort D2T RA vs non-D2T RA vs HC
91% D2T RA
Higher catastrophizing
Higher pain sensitivity
More emotion-focused coping strategies
“Chronic pain-like” profile
Associated with higher CNS related gene expression NRG1 https://t.co/nkQco73vqI
Aurelie Najm AurelieRheumo ( View Tweet)
Oral GLP1s now coming to the market-Peptide based (can be given only on empty stomach),
Non peptide based (can be given anytime). Know about s/e and contraindications.
May have Rheumatic diseases indications soon. Imp for rheumatologists to be familiar.
#EULAR2026 @RheumNow https://t.co/KNudYN29PT
Links:
Bella Mehta bella_mehta ( View Tweet)
Sad to see this but important to be aware. Increasing risk of suicide using colchicine in Familial Mediterranean Fever. #POS0768 #EULAR2026 @rheumnow.
Average age 28! 87%female, only 7 % with psychiatric referral!
Retrospective 15 pts. https://t.co/241SE6O395
Links:
Bella Mehta bella_mehta ( View Tweet)
#OP0241 FASTLANE phase 4 trial showed TOFA was superior to PBO in early active axSpA, achieving significantly higher ASDAS inactive disease rates at 16 weeks (26.4% vs 7.4%) on background of naproxen. MRI osteitis improvement numerically favoured TOFA. #EULAR2026 @RheumNow https://t.co/dGETjkmfrh
Mrinalini Dey DrMiniDey ( View Tweet)
Impt pts to consider in D2T CLE by Prof Wittmann:
If tx is not working, ask yourself: is the dx correct? adherence?
Main message: treat early
When damage is present, tx doesn’t really provide considerable improvements
Future drxns? Endotype-directed tx
@Rheumnow #EULAR2026 https://t.co/hB48aD7jx5
Links:
sheila RHEUMarampa ( View Tweet)
#OP0240 phase 3 data showed that the pan-JAK inhibitor gecacitinib significantly improved disease activity, function, MRI inflammation and quality of life in active radiographic axSpA versus placebo at 16 weeks, with ASAS40 responses of 51.9% vs 12.9%. #EULAR2026 @RheumNow https://t.co/6oojvvFmk0
Mrinalini Dey DrMiniDey ( View Tweet)
Weight management should be discussed!!
Obesity management will help rheumatic diseases. EULAR guidelines below. No ACR ones exist.
Best evidence in OA and Gout.
#EULAR2026 plenary @RheumNow https://t.co/hBu4YeXZbu
Bella Mehta bella_mehta ( View Tweet)
Metaflammation !! A new term I learnt at #EULAR2026 plenary. @RheumNow
Inflammation triggered by metabolic abnormalities.
This may be the reason a lot of our inflammatory arthritis patients on GLP1 drugs(other indications) have thier disease activities improving. Emerging data.
Bella Mehta bella_mehta ( View Tweet)
#OP0239: validating 2025 ASAS-SPARTAN axSpA classification criteria in the SPACE cohort. Revised criteria showed high specificity but lower sensitivity than 2009 criteria, reflecting greater emphasis on imaging & less reliance on clinical features alone. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Catching your breath session at #EULAR2026
RA-ILD is heterogeneous, maybe under-recognized and risk stratification remains a challenge (Pierre-Antoine -Jugr)
Screening for RA-ILD is only as good as availability of early intervention and treatment (Jeff Sparks)
@RheumNow https://t.co/V1JXM3i9wP
Links:
Jiha Lee JihaRheum ( View Tweet)
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026: Industry Press Releases
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will https://t.co/2czkdWKtEO
Dr. John Cush RheumNow ( View Tweet)
Why are GLP1 agonists important in rheumatology- plenary at #EULAR2026
Presence on leucocytes- change from pro inflammatory to anti inflammatory casade
Also in fibroblasts in rheumatoid arthritis.
Trials on the way for OA, Gout, as well as IBD. @RheumNow https://t.co/WJ6actAzrv
Links:
Bella Mehta bella_mehta ( View Tweet)
#OP0238: French SNDS cohort found longer exposure to targeted therapies in SpA (>6months) was assoc with a lower overall cancer risk vs shorter exposure, esp for haematologic malignancies. Data add to long-term safety evidence for targeted therapies in SpA. #EULAR2026 @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#OP0237 reports positive phase 3 data for the selective JAK1 inhibitor ivarmacitinib in active nr-axSpA. ASAS40 responses at Week 12 significantly higher vs placebo (39.7% vs 24.8%), with sustained efficacy through Week 24 and no new safety signals observed. #EULAR2026 @RheumNow https://t.co/JZLQ0Ywlio
Mrinalini Dey DrMiniDey ( View Tweet)
Prof. Wittmann discusses the current tx for CLE using a stepwise approach.
Smoking is a challenge in D2T skin #lupus due to data showing that smoking reduces efficacy of antimalarials & worsens dse act & damage.
Advocate for smoking cessation!
@Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ
Links:
sheila RHEUMarampa ( View Tweet)
Evidence on diet changing prognosis or incidence of rheumatic diseases is limited. However overall need to encourage health diets. Plenary at #EULAR2026 @RheumNow
Summary below. https://t.co/QC0Li38eh6
Bella Mehta bella_mehta ( View Tweet)
